Alkermes plc (ALKS) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alkermes plc Reports Third Quarter 2015 Financial Results
October 29, 2015 7:02 AM EDTThird Quarter Revenues of $152.7 Million and Non-GAAP Diluted Loss Per Share of $0.18
Commercial Launch of ARISTADA Underway Following FDA Approval for the Treatment of Schizophrenia on Oct. 5, 2015
ALKS 3831 for Schizophrenia and ALKS 8700 for Multiple Sclerosis to Commence Registration Studies Before Year-End
DUBLIN--(BUSINESS WIRE)-- Alkermes plc (NASDAQ: ALKS) today reported financial results for... More
